6 datasets found
-
Federal
Debate: Does it matter how you lower blood pressure?
U.S. Department of Health & Human Services —
Whether it matters how pressure is lowered has been debated since antihypertensive drugs proved to prevent cardiovascular events. However, in clinical trials, while... -
Federal
How long should angiotensin-converting enzyme inhibitors be given to patients following myocardial infarction: implications of the HOPE trial
U.S. Department of Health & Human Services —
Long-term treatment with angiotensin-converting enzyme inhibitors reduces post-infarction morbidity and mortality in patients with left ventricular (LV) systolic... -
Federal
A new era in hypertension research: discussing the findings of ALLHAT
U.S. Department of Health & Human Services —
The key question in hypertension research today is, "Does it matter how elevated blood pressure is lowered?" The Antihypertensive and Lipid-Lowering Treatment to... -
Federal
Are statins anti-inflammatory?
U.S. Department of Health & Human Services —
Large scale clinical trials demonstrate significant reductions in cardiovascular event rates with statin therapy. The observed benefit of statin therapy, however, may... -
Federal
Treating patients with low high-density lipoprotein cholesterol: choices, issues and opportunities
U.S. Department of Health & Human Services —
Three clinical trials have recently focused on the benefits of lipid-regulating therapy in populations with normocholesterolaemia and low high-density lipoprotein... -
Federal
A Review of the Adverse Effects of Peripheral Alpha-1 Antagonists in Hypertension Therapy
U.S. Department of Health & Human Services —
Background Doxazosin and its role as an antihypertensive agent have come under recent scrutiny as a result of the early termination of that treatment arm in ALLHAT....
6 datasets found